<DOC>
	<DOCNO>NCT00973232</DOCNO>
	<brief_summary>The objective two-part study compare single-dose multiple-dose pharmacokinetics extend release immediate-release fix combination formulation contain tramadol-HCl/acetaminophen evaluate effect food extended-release formulation .</brief_summary>
	<brief_title>A Comparative Bioavailability/Food Effect Study Immediate-Release Extended-Release Tramadol HCl/Acetaminophen Combination Products Following Single-Dose Multiple-Dose Administration Healthy Adult Volunteers</brief_title>
	<detailed_description>- To compare single ( Part A ) multiple dose ( Part B ) pharmacokinetic profile bioavailability DDS-06C tablets immediate-release tablet reference product Zaldiar® Ultracet® . - To assess effect food pharmacokinetic profile DDS-06C tablet follow administration single oral dose . - To monitor record adverse event .</detailed_description>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Adult male female age 1855 year inclusive body mass index ( BMI ) 1830 kg/m2 Healthy determine prestudy medical history , physical examination 12lead ECG Clinical laboratory test within reference range clinically acceptable Investigator Negative hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) I II test screen Negative drug abuse alcohol screen admission Nonsmokers least 3 month precede screen If female , currently pregnant breast feed use medically acceptable method contraception male , female partner use medically acceptable method contraception Able willing give write informed consent . Subjects conform inclusion criterion Female subject pregnant , try become pregnant , lactate use acceptable method contraception Clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder Clinically relevant surgical history Clinically relevant family history History relevant atopy History relevant drug hypersensitivity History alcoholism History drug abuse Male subject consume 21 unit alcohol week female subject consume 14 unit alcohol week Significant infection know inflammatory process screen Acute gastrointestinal symptom time screen and/or admission ( e.g . nausea , vomit , diarrhoea , heartburn ) Acute infection influenza time screen admission Use prescription drug within 7 day first dose , unless agree non clinically relevant Principal Investigator Sponsor Use overthecounter medication exclude routine vitamin include mega dose vitamin therapy within 14 day first dose , unless agree non clinically relevant Principal Investigator Sponsor Use investigational drug participation clinical trial within 3 month first dose Donation receipt blood blood product within previous 3 month prior first dose Vegetarians , vegans medical cultural dietary restriction . Inability communicate reliably Investigator . Subjects unlikely cooperate requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Tramadol</keyword>
	<keyword>Acetaminophen</keyword>
	<keyword>combination</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>bioavailability</keyword>
	<keyword>Zaldiar</keyword>
	<keyword>Ultracet</keyword>
	<keyword>fed</keyword>
	<keyword>fast</keyword>
	<keyword>single-dose</keyword>
	<keyword>multiple-dose</keyword>
	<keyword>healthy</keyword>
	<keyword>volunteer</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>